Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii

13 Oct 2020

Abstract excerpt

OBJECTIVE: This study presents real-life experience with cefiderocol used on a compassionate basis for treatment of three patients with severe infections caused by extensively/pan-drug resistant (XDR/PDR) Acinetobacter baumannii (Ab). METHODS: Serum bactericidal activity was determined and considered as a surrogate of cefiderocol susceptibility. RESULTS: Clinical improvement and microbiological eradication of A....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Infections and bacterial resistance
Share to Nosocomial Infections in ICU

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33065329
DOI: 10.1016/j.jgar.2020.09.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumanniiPMID 33065329Read ↗

Real‑world effectiveness and safety of cefiderocol in critically ill patients with MDR Gram‑negative infections: Results from a retrospective studySemantic proximity Read ↗

Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE StudySemantic proximity Read ↗

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance MechanismsSemantic proximity Read ↗

Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging DataSemantic proximity Read ↗

In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitalsSemantic proximity Read ↗

Cefiderocol in Combating Carbapenem-Resistant Acinetobacter baumannii: Action and ResistanceSemantic proximity Read ↗

Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant <i>Acinetobacter baumannii</i> patient isolates with diverse resistance mechanismsSemantic proximity Read ↗

Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant MechanismsSemantic proximity Read ↗

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical TrialsSemantic proximity Read ↗

Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-IDSemantic proximity Read ↗

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance ProgramSemantic proximity Read ↗

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii IsolatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.